ANRS Infectious emerging diseases (MIE), autonomous agency of Inserm, facilitates, evaluates, coordinates and funds research into HIV/AIDS, viral hepatitis, sexually transmitted infections, tuberculosis and emerging and re-emerging infectious diseases.
A central role in infectious diseases research for over 35 years
Supporting research to prevent, understand and treat infectious diseases
ANRS MIE three majors levels of action
ANRS MIE is an agency operating under the specific status of an autonomous agency within Inserm.
Patient associations, next generation of scientists, quality and ethical approach, open science
Our agency funds, coordinates, evaluates and facilitates research into HIV/AIDS, viral hepatitis, sexually transmitted infections, tuberculosis and emerging infectious diseases.
Learn more about the diseases and pathogens covered by our research
Information on the projects we fund
Our workgroups bring together researchers and representatives of civil society
Guiding and advising innovative project leaders
The agency supports a number of research platforms and networks to federate and help shape research in its field
National and international research platforms supported by the agency and designed for the scientific community
Clinical research networks and networks of young researchers
Access to data and biological collections from research promoted by the agency
The agency is a member of various networks and forges partnerships with national and international associations, organisations and initiatives
Partner sites, international global health research platforms, ad hoc partnerships
WHO, Ministry of Europe and Foreign Affairs, Global Health EDCTP3 Joint Undertaking, structuring networks
Strategic international projects and capacity-building programmes
Fighting epidemics: ANRS MIE leads WHO filovirus CORC
Collaboration with community stakeholders
Each year, the agency offers two calls for generic projects and calls for thematic projects. Some are jointly carried out with other research players
Agency's current, forthcoming and completed calls for proposals
Find out the list of calls for projects previously funded by the agency
Find out the Start programme, here to support and guide the next generation of scientific researchers
ANRS MIE is at the forefront of crisis preparedness and response.
Facilitation and watch procedure for responding to emerging or re-emerging epidemics.
ANRS MIE continues to follow influenza closely since June 2024.
This Outbreak Response Unit for several diseases is active since March 2025.
Opened since January 2025 and still active since the detection of one new case in French Guiana in January 2026.
A level 1 Outbreak Response Unit since December 2023, monitoring new cases in Mayotte and La Réunion.
Discover every Outbreak Response units.
Submit a project
Find out successful aplications.
Last updated on 12 February 2025
Share:
Trier par
PETITDEMANGE CAROLINE
Allocation de recherche
12
MARQUEVIELLE Julien
ZZ BENKIRANE Monsef
36
GROUX Nicolas
Colloque
1 200 €
GROUX Nicolas | MabDesign GROUX Nicolas MabDesign Association 17 Rue Crépet 69007 Lyon France
Le projet MYCOCIDALTOX vise à développer de nouvelles stratégies thérapeutiques pour lutter contre la tuberculose (TB). Nous avons récemment identifié et caractérisé deux toxines associées à des systèmes toxine-antitoxine (TA) de Mycobacterium tuberculosis qui sont bactéricides en l’absence de leur antitoxine. Nous utiliserons un criblage ciblé de chimiothèques sur cellules entières pour identifier les composés capables de déstabiliser l’interaction toxine/antitoxine ou de stimuler la dégradation des antitoxines, déclenchant ainsi une létalité dépendante de la toxine. Les résultats obtenus seront validés in vitro et dans des cellules infectées, seuls ou en combinaison avec des antituberculeux standards.
Ce contrat d’initiation nous permettra d’établir la preuve de principe qu’utiliser des composés ciblant les systèmes TA bactéricides constitue une approche prometteuse pour le développement de nouveaux antituberculeux ; il constituera la base d’un futur projet plus ambitieux qui inclura des criblages plus volumineux, l’amélioration des composés par la chimie médicinale, des études de mode d’action et des validations précliniques dans des modèles animaux. Le ciblage des systèmes TA bactéricides pourrait aider à identifier de nouvelles stratégies thérapeutiques à utiliser en complément des antibiotiques standard pour améliorer le traitement de la tuberculose, en particulier dans le contexte du nombre croissant de souches de M. tuberculosis résistantes aux antibiotiques.
NEYROLLES Olivier
Contrat d'initiation
19 999 €
NEYROLLES Olivier | CNRS UMR 5089 NEYROLLES Olivier CNRS UMR 5089 Institut de pharmacologie et de biologie structurale 205 route de Narbonne 31077 Toulouse Cedex 04
CARACOTA Elizabeth
DEPREZ Eric | Laboratoire de Biologie et Pharmacologie Appliquée CNRS UMR8113 DEPREZ Eric Laboratoire de Biologie et Pharmacologie Appliquée CNRS UMR8113 ENS-Paris-Saclay 4 avenue des Sciences 91190 Gif-sur-Yvette France
FEREDJ Elsa
LYONNET Stanislas | U1163 LYONNET Stanislas U1163 IHU Institut Imagine 24 boulevard du Montparnasse 75015 Paris France
HANKINS Catherine
15 000 €
HANKINS Catherine | Amsterdam Institute for Global Health and Development HANKINS Catherine Amsterdam Institute for Global Health and Development AHTC Tower C4 Paasheuvelweg 25 1105 BP Amsterdam The Netherlands
MAARIFI GHIZLANE
MESNARD Jean Michel | CNRS-UMR 9004 IRIM MESNARD Jean Michel CNRS-UMR 9004 IRIM Institut de recherche en infectiologie de Montpellier 1919 route de Mende 34293 Montpellier cedex 5 France
